Amongst the proposals agreed by Council was to move towards an independent appointment system for Council membership to replace the current election system.
In addition, Council voted:
Council was tied on whether to separate the position of RCVS President and the Chair of RCVS Council, meaning that this will come back for decision at a later date following the consultation.
RCVS President susan paterson, said: “The unique way that RCVS Council is currently constituted with annual elections to Council is an old model of self-regulation which is no longer found in other professions including doctors, nurses, pharmacists, solicitors and social workers, among others.
“As a responsible regulator we have a duty to operate in a way that recognises modern principles of regulation, and best meets our objectives to enhance society through improved animal health and welfare by setting, upholding and advancing the educational, ethical and clinical standards for the veterinary professions.
"The College’s recommendations would see us retain self-regulation in the sense of independence from government, and maintain registrants within our governance framework, while better assuring the public that we are acting on their behalf.
“It is our firm belief that, among other things, moving to an all-appointed Council member system, whereby those who serve on Council are selected via an independent process based on their knowledge and experience to ensure input from all parts of the veterinary sector, will better serve our aims, as will having a better balance of professional and lay members.
"Of course, veterinary expertise, knowledge and experience will also remain a vital part of any future arrangements throughout our committee structure, so the veterinary voice will be as important as ever in our policy and decision-making processes.
rcvs.org.uk/who-we-are/rcvs-council/council-meetings/18-january-2024/
Further details about the consultation process will be published in due course.
Discuss here: https://www.vetsurgeon.org/f/non-clinical-questions/30878/what-do-you-think-about-the-rcvs-proposals-to-stop-council-elections-and-move-to-appointed-members-with-equal-or-almost-equal-number-of-lay-members/243481
Eukanuba has published the results of a 10 year study to evaluate the health and longevity of continuously Eukanuba-fed dogs, in which 90% lived beyond the breed's typical lifespan.
Before the start of the study, a independent panel of veterinary academics and experts assessed existing evidence concerning the longevity of Labrador Retrievers and came to a consensual conclusion that the average lifespan for the breed is 12 years.
39 Labrador Retrievers in early to mid-adulthood were then enrolled in the study1, which began in 2004. All the dogs were neutered and had identical housing, standardised daily care and veterinary care. The dogs were fed the amount of food needed to maintain each dog within an optimal body condition score.
Remarkably, 28% of the dogs in the study achieved exceptional longevity, living beyond 15.6 years. One dog very nearly made it to 18 years of age.
The study was overseen Eukanuba's Longevity Council, a panel of international vet and industry experts including Professor Stuart Carmichael, Dr Penny Watson, Dr Vicki Adams, Professor Steve Dean and David Morgan, which collectively agreed that the secret to healthy ageing in canines is a careful balance of nutrition, good husbandry and effective veterinary care.
Professor Steve Dean, Former Chairman of the UK Kennel Club said: "Nutrition is a major contributor to the health of dogs in the long term, of course it isn’t the only contributor; good husbandry and good veterinary care are the other major pillars for health and longevity. The correct nutrition has a big part to play in maintaining dog health throughout its entire life, which we’ve found out from the Eukanuba Long Life Observation, can be a lot longer than we have previously expected. We’ve always assumed that Labradors will live 12 years if we’re lucky, but now we have a whole new target to aim for…16 and 17 years. It is quite phenomenal."
Dr Penny Watson, Senior Lecturer in Small Animal Medicine, Queen’s Veterinary School Hospital, University of Cambridge said: "Vets as a profession are very good at treating diseases in animals, but perhaps slightly less good at giving preventative advice to pet owners about healthy lifestyles. As vets, we should be thinking all through an animals life cycle, from puppy to geriatric, about the preventative aspects, such as good diet, maintaining the right body condition score and other aspects including dental care, rather than just looking disease and treating it."
David Morgan, Eukanuba’s Senior Scientific Communications Manager said: "The hope is that we can take the message that it’s not only about nutrition but what we call appropriate care, which is veterinary care and husbandry, looking after the dogs in a responsible way. Because, yes we have some great observations and we are starting now with Dr Vicki Adams to break down into more detail what we’ve actually seen in the Eukanuba Labradors and what recommendations we can give in the future so that all dogs can have that longer, healthy and more vibrant lives."
Reference
The British Veterinary Association has expressed concern following the announcement by the University of Surrey that it is launching a new school of veterinary medicine, with the first cohort of students due to start in 2014.
Peter Jones, President of the BVA, said: "Reports of a new veterinary course at the University of Surrey will be of significant concern to our members, particularly veterinary students and recent graduates.
"We are already seeing an increasing intake of students at the existing veterinary schools. Another veterinary course will place even more graduates onto the veterinary employment market putting significant pressure on the employment prospects of individual graduates.
"It could also impact on the ability of the profession to accommodate the increasing demand for extra mural studies (EMS) placements and the ability of all schools to continue to provide high quality education and high quality teaching staff.
"The end result could be an oversupply of highly qualified veterinary surgeons carrying significant amounts of debt unable to find employment within the profession.
"New graduates are already reporting difficulties in finding their first jobs with some saying that it takes 6 to 9 months.
"Last year the veterinary profession was removed from the Home Office's shortage occupation list because it became apparent that we currently have sufficient veterinary surgeons to meet demand. Another veterinary course could tip the balance too far the other way.
"The news from the University of Surrey also illustrates that a greater oversight of the number of veterinary graduates coming onto the market is badly needed to properly plan future requirements of the veterinary profession in the UK."
Davies says the new treatment is appropriate for dogs with severe diffuse elbow dysplasia, where cartilage wear results in bone rubbing against bone, called medial compartment disease (MCD). In these cases, Davies says that the prognosis is typically poor but now CUE is providing a promising alternative surgical option when arthroscopic and non-surgical options have failed.
The surgery involves partial resurfacing of the elbow joint. By focusing on the specific area of disease in the medial compartment, the CUE implant provides a less invasive bone-sparing option for resurfacing the bone-on-bone medial compartment while preserving the dog’s own good cartilage in the lateral compartment. Davies says that in most dogs, the technique significantly improves the pain and lameness that was caused by bone-on-bone grinding.
Unlike total elbow replacements, CUE does not require major bone cutting. On average, recovery tends to be significantly faster with progressive improvement peaking six months after surgery.
Mike Farrell, EBVS European and RCVS Specialist in Small Animal Surgery (Orthopaedics) at Davies recently performed a successful CUE procedure on Rubee, an 11-year-old Labradoodle diagnosed with severe MCD. At the recheck, six weeks after surgery Mike said: "Rubee’s early response to CUE has been nothing short of astonishing. I would have been pleased if she had made the improvement seen today after six months rather than six weeks."
Louise Clark Head of Anaesthesia and the Pain Clinic at Davies Veterinary Specialists continued: "CUE potentially provides a surgical alternative for what is currently an incredibly frustrating condition to manage and one that causes animals a lot of pain, and owners a great deal of angst.
"Arguably it is an ethically robust procedure because it can dramatically reduce patient pain with a relatively well defined risk of complications in a patient cohort that is otherwise at risk of euthanasia because of elbow disease."
For more information, visit: https://vetspecialists.co.uk/services/orthopaedics/
Paragon is being built by the Linnaeus Group, which says the new centre will be one of the largest and best-equipped in the UK when it opens its doors early in the New Year.
The new centre follows the Linnaeus Group's acquisition of Dewsbury-based Calder Vets last year.
Calder Vets' existing referral teams, together with two ophthalmologists from its Mirfield branch, will be transferring to Paragon. Meanwhile, Calder Vets will move to solely first-opinion work.
Currently nearing the end of construction, the centre will have eight consulting rooms, five operating theatres, MRI and CT scanners, intensive care facilities along with an all-digital imaging department.
A total of up to 80 staff will be employed at Paragon, including up to 18 referral vets and 32 veterinary nurses.
Specialist services will include cardiology, neurology, ophthalmology and orthopaedic and soft tissue surgery.
Positions currently available include a diagnostic imager, internal medicine specialist, neurology specialist, oncology specialist and an ophthalmologist, as well as various nursing posts.
Ian Monteith, managing director of Paragon, said: "We are looking for the best possible people who not only have the right skills and experience, but who will also fit into the ethos we want to create at Paragon.
"It is a significant and exciting opportunity for motivated, high calibre people to help shape something that has a very bright future for both the industry and for their own careers.
"Our philosophy is very much one of friendly cooperation between all members of staff, creating a pleasant, supportive and good-humoured atmosphere."
For details of the vacancies currently on offer at Paragon, visit www.paragonreferrals.co.uk/en-GB/careers
The Allium species includes onions, garlic, and their relatives. All members of the Allium family are poisonous to cats and dogs and even minimal amounts can be dangerous. For example, a 5kg cat would only need to ingest 1-2 garlic cloves to show clinical signs. Poisoning causes haemolytic anaemia with treatment being supportive, as there is no antidote. In severe cases blood transfusions may be required.
Powdered versions of these plants are more concentrated and are often used in gravy and stuffing in the traditional Christmas dinner, so toxicity can occur much more easily.
Will Peel, Product Manager at TVM UK said: "Alliums are toxic to animals and as there is no antidote it’s important that veterinary staff are fully prepared and are able to react quickly and provide the best care possible.
"Our focus is on helping veterinary staff prepare for all eventualities so we hope that these new guidelines will prove beneficial."
The guidelines can be downloaded for free from https://www.tvm-uk.com/vet-resource-library/.
DVS highlights that the phenomenon of large group veterinary businesses is on the rise: big corporations such as Pets at Home Vet Group have recently bought stakes in several of the UK’s biggest referral practices and CVS Group, for example, now owns more than 360 of the UK’s veterinary surgeries, including referral practices.
By contrast, Davies Veterinary Specialists has now reduced the shareholdings of its founder (Jerry Davies), financial director (Mike Thomas) and managing director (Clive Elwood), in order to increase the holdings of Ian Battersby (internal medicine), Ronan Doyle (soft tissue surgery), David Gould (ophthalmology) and Nat Whitley (internal medicine) and create 8 new shareholders: Louise Clark (anaesthesia), Nuria Corzo-Menendez (diagnostic imaging), Mike Farrell (orthopaedic surgery), Laurent Garosi (neurology), Mark Goodfellow (oncology), Patricia Ibarrola (internal medicine), Pedro Oliveira (cardiology), Peter Smith (neurology).
The company says that its increasing number of shareholders will build a more effective business democracy, and in turn help uphold its core values of integrity, professionalism, compassion and respect.
Clive Elwood said: "Maintaining our independence is important to us as a business because it ensures we retain the culture and ethos that provides leading multi-specialist care to all of our patients and exceptional service to our customers and referring colleagues.
"I am delighted we have managed to achieve this transaction, which represents the next stage in the development of our amazing practice. Retaining ownership means we can demonstrate that there remain alternative business models and career paths outside corporate practice. It is a pleasure to welcome such a fantastic group of new shareholders who will, I am certain, contribute greatly to our future success."
DVS says it will continue to evolve the management and governance structure of the practice as it grows. In the future DVS shareholders will set overall strategy and direction for the business and ensure effective governance by the Board of Directors. As well as clinical skills, the development of management and leadership skills will be encouraged across the practice. A strong commitment to learning, research, innovation and teaching will support the delivery of exemplary patient care.
To find out more visit www.vetspecialists.co.uk
Simon Boulton MRCVS, Marketing Manager at TVM said: "Traditional activated charcoal is slow, complex and often messy to prepare. Carbodote is different – a simple, ready-to-use preparation that can be quickly and easily administered to patients when they have eaten something that you want to help adsorb. Carbodote coats the gut wall where it adsorbs elements non-specifically - thus limiting the absorption of unwanted molecules, whether solid, liquid or gaseous. Studies have also shown that Carbodote also has greater adsorbancy that other products on the market1."
Carbodote is stable and homogenous solution with no mixing required. TVM says it will even pass down nasogastric tubes. It comes pre-prepared in bottles of 100ml - enough for a 20kg dog.
TVM says activated charcoal can be used as an aid to the management of multiple poisonings and the company has created a list of the adsorbancy potential of activated charcoal for a variety of poisons.
For more information about Carbodote, speak to your local Territory Manager, email help@tvm-uk.com, visit www.tvm-uk.com, or call TVM on 01737 781 416
The NSAID's new indication is in addition to its existing license for acute pain and inflammation.
Elanco points to research it carried out which found that over a six week period, owners saw a visible improvement in their cats' performance of daily activities. There was also a 50% reduction in owner-assessed pain and disability (significantly greater than seen in the placebo group)1.
The company says the product, which is administered once-daily as a small flavoured tablet, is well-accepted by most cats, and has a robust safety profile2. It is also a winner of an ISFM Easy to Give Award.
Elanco's Veterinary Technical Consultant, Lepha McCartan said: "It is very exciting to be launching this new indication for Onsior because musculoskeletal disorders are commonplace in cats.
"Although reports vary, studies have shown that radiographic evidence of DJD has a prevalence as high as over 90%.3
"At Elanco we are passionate about keeping cats doing what they love and Onsior enables this while also giving vets more choice for managing chronic musculo-skeletal disease."
For more information, visit: myelanco.co.uk or speak to your Elanco territory manager.
References
In the study titled 'Staphylococcal bacterial contamination of portable electronic devices in a large veterinary hospital1', samples were taken from the screen and any button of PEDs (such as mobile phones and tablets) of staff working directly with feline and canine patients. Hospital staff were asked to complete a questionnaire to ascertain the frequency of PED use and the frequency and method of PED cleaning.
The aim of the study was to determine the prevalence of Staphylococcal contamination of PEDs in a veterinary hospital, and to identify the source and determine the pathogenesis of any cultured strains.
Positive cultures were tested for resistance to oxacillin and vancomycin using a Kirby-Bauer disc diffusion test and then by using a broth microdilution test to EUCAST guidelines and breakpoints. PCR was used to specifically genotype the isolated staphylococci.
Georgia Vinall, corresponding author for the paper, said: “Useable swab samples were taken from 47 devices. Staphylococcus spp. were cultured from 68% of PEDs with a median of 10 colonies grown per device. Vancomycin-resistant Staphylococcus spp. were found on 36% of devices, whilst oxacillin-resistant Staphylococcus spp. were cultured from 2% of devices. DNA sequencing identified three Staphylococcus species; S. capitis, S. epidermidis and S. hominis which are most likely associated with humans as either sources or transmission vectors."
“The results of the survey indicate that 96% of staff had a PED which they used in the hospital environment, of which 85% use their device every day. Despite the high usage of PEDS in the hospital environment, only 6% of staff cleaned their device daily, with 33% of staff cleaning their PED less than weekly. Furthermore, only 54% of staff cleaned their device with a disinfectant."
Nicola Di Girolamo, Editor of JSAP said: "This study demonstrates that PEDs may become contaminated with potentially pathogenic microorganisms. Although this specific study did not focus on transmission of these microorganisms, and therefore it is unclear what are the clinical implications of this finding, it seems prudent to develop appropriate protocols for cleaning of PEDs in veterinary hospitals."
The full article can be found in the April issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13289.
Dorset-based homeopathic practitioner Philippa Rodale, who requested that her name be removed from the RCVS Register in July, has been convicted of cruelty at Weymouth Magistrates Court.
The case related to Mrs Rodale's treatment of a female foxhound called 'Dangerous', which had been brought to her after being hit by a car.
The dog was reported to the RSPCA by a member of the public who was alarmed after seeing the dog lying in the surgery, whining and dragging her back legs. The court heard that at this point, Dangerous had already been in the care of the clinic for 10 days, during which time Mrs Rodale had administered both homeopathic and conventional treatment, but had failed either to x-ray the animal or give adequate pain relief. In addition, the court heard hygiene and nursing care standards were poor.
RSPCA inspector Marie Griffiths said: "When I found Dangerous she was just lying on a tiled floor with no bedding and only a towel propping up her head, paralysed, and covered in infected pressure sores. She couldn’t even stand up.
"It was a shocking sight and definitely not something that I would ever expect to see anywhere, let alone in a veterinary practice.
"She was clearly in agony and had just not received the level of care and attention that you would expect from a vet. She was suffering so much that sadly a decision had to be made by another veterinary surgeon to do the kind thing and finally put her to sleep.
"The RSPCA exists to protect animals from cruelty and suffering and to defend them when their needs are not being met and we hope that this case goes some way to showing that no-one is exempt from providing animals with the duty of care that they deserve - not only morally, but because it is also the law.”
Mrs Rodale was ordered to pay £4,000 in costs to the RSPCA as well as £520 in court charges and a £15 victim surcharge.
Do you think the RCVS should issue a public statement about homeopathy, and require that veterinary surgeons inform owners about the scientific evidence which demonstrates it is ineffective? If so, visit The Campaign For Rational Veterinary Medicine, and sign the petition.
Picture BNPS
Participants travel around South Africa working on game reserves, commercial farms and in poor communities, getting experience of game capture, providing veterinary care in townships and rural areas, working in a private clinic and handling and treating large farm animals.
There are also a range of weekend activities, including kayaking, quad biking, game drives, horse riding, surfing, beach walking, bars and restaurants.
Kim said: “We’ve designed the programme so that it’s suitable for people with a wide range of experience, including veterinary and veterinary nursing students, young people considering a career in the veterinary profession and animal lovers.”
For more information, visit: wildinsideadventures.com
The research on which the new indication is based is described by Boehringer as the largest and most cutting-edge study in veterinary cardiology.
The EPIC study (Effect of Pimobendan in Dogs with asymptomatic MVD and Cardiomegaly)1 demonstrated that Vetmedin delayed the onset of heart failure for dogs with asymptomatic MVD, providing on average 15 months additional symptom-free time, as well as extending overall survival.
Indeed, Boehringer says the worldwide study was so conclusive - involving 360 dogs, in 36 centres, in 11 countries across four continents - that it was terminated early as it was deemed unethical to withhold Vetmedin from dogs in the placebo group.
Panny Morgan, Vetmedin brand manager at Boehringer Ingelheim, said: "Vetmedin delays the onset of heart failure in dogs with asymptomatic MVD and cardiomegaly, providing 15 months extra symptom-free time; that’s almost 10% of a dog’s lifetime.
"Prescribing Vetmedin to dogs with an MVD murmur and enlarged heart will not only extend a dog’s lifespan, but it will also have a major impact on their quality of life."
For further information on Vetmedin, contact your Boehringer Ingelheim territory manager or visit www.vetmedin.co.uk.
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
Bimeda has announced the UK launch of Selenate LA, for selenium deficiency in calves and adult cattle.
Bimeda's Head of Technical Services, Padraig Hyland MVB said: "The slow release product provides raised selenium levels for a full 12 month period. When injected, Selenate LA forms a reservoir under the skin and its low solubility sees an even release of selenium over a year. But it's not just the efficacy of Selenate LA that make it such a stand out product, it's the convenience too".
Bimeda says the health properties of Barium Selenate in selenium deficient herds are well documented, from prevention of white muscle disease, anoetrus and mastitis, to improved conception rates and milk yield¹.
However there are various choices for farmers when dealing with selenium deficiency.
Padraig said: "The beauty of Selenate LA is that it is one injection, once a year. You know exactly how much each cow is getting so it's very predictable. And with many farmers already time short, it makes selenium supplementation extremely straightforward and cost effective."
Selenate LA is a POM-V medicine and can be offered by veterinary surgeons based on serum levels of glutathione peroxidase from a representative sample of the herd, or as part of a herd health and fertility plan. Padraig said: "It allows vets to offer a cost-effective and licensed alternative to oral supplements, with the added piece of mind only an injection can bring.
"The long-lasting and effective levels of selenium allow injection of the dam at any time, including mid to late pregnancy, to ensure good selenium levels in the new-born calf. This also prevents those post-calving complications such as retained foetal membranes, metritis and poor calving to conception times, where selenium deficiency has been implicated".
The company confirms that there is no milk withdrawal period and a thirty one day meat withdrawal for the product. Selenate LA is administered via a subcutaneous injection from a multi-dose bottle. For further information contact Andrew Lane, Bimeda UK Sales Manager on 07917 208524.
1. 1987 (Taranaki, North Island)
The data shows a stable population of 12m pets, as follows:
There were also:
The survey also provides an interesting point at which to note some historical trends. Whilst cats and dogs have always been the most popular pets, 50 years ago it was budgerigars that held third place. Since then, the dog population has grown 76% and the cat population has grown 63%, whilst rabbits have moved into third place.
Nicole Paley, PFMA Deputy Chief Executive, said: "Almost half of UK households are benefitting from pet ownership and whilst cats and dogs continue to be the most popular pets, rabbits came in at third place followed by indoor birds, guinea pigs and domestic fowl.
"A key role of PFMA is to provide educational resources on how to ensure the full range of pets get the right nutrition and we really value the role of vets and vet nurses being at the front line to pass this information on.
"At PFMA we are here to support the veterinary profession and we have a series of factsheets on popular feeding topics such as ‘Do all small mammals eat the same food’ and ‘Nutrition for indoor birds. Our pet companions fill our lives with love and joy and in return, it’s important we provide the care they need. "
For more information, visit www.pfma.org.uk/statistics
95% of the vets surveyed by the company reported success treating cats with Thyronorm Oral Solution for Cats, while 89% expected the liquid solution to improve compliance in the management of hyperthyroidism.
93% also said they found Thyronorm gave them an easier way to offer cats a low dose, or an 'in-between' dose, as it can be titrated 'to effect' – meaning the dose of treatment can be varied more easily to suit the individual animal.
Feline hyperthyroid specialist Dr Sarah Caney said she is unsurprised by the survey results: "Treatment is complex for cats needing a low dose, or an ‘in between’ dose, as standard anti-thyroid tablets are only available in a small number of dose sizes and are not designed to be split, halved or quartered. Also, if a cat is on alternating doses, it can be difficult for carers to remember which dose is due today."
Rachel Crowe, Norbrook’s Companion Animal Senior Product Manager, said: "We are delighted that overall 99% of the 200 veterinary surgeons surveyed would recommend Thyronorm in the management of hyperthyroidism, compared to other medical options."
Thyronorm contains 5mg/ml of thiamazole (methimazole). The initial starting dose is 5mg active ingredient per day, split into two doses.
Available in 30ml and 100ml bottles, with an in-use shelf life of six months, Thyronorm is available to order from all UK veterinary wholesalers.
Genitrix has launched Libromide, the first licensed formulation of potassium bromide for the treatment of canine epilepsy, following what the company believes to be the largest ever trial of dogs suffering from epilepsy.
Genitrix says the availability, for the first time, of a licensed formulation of potassium bromide should give veterinary surgeons and pet owners the reassurance that the rigorous authorisation process provides. It ensures, for instance, that the product has been developed especially for dogs and that it is manufactured in accordance with EU regulations. It also ensures that the product has been extensively and independently trialled, proven to be efficacious without adverse reactions, and that the necessary pharmacovigilance is in place to support it.
The company also says that the availability of a licensed product paves the way for more comprehensive information to be provided to veterinary surgeons on the use of potassium bromide in treating seizures. The Veterinary Medicines Directorate (VMD) imposes restrictions on educational materials supplied by manufacturers of unlicensed products, an approach which has created a 'knowledge gap' among many veterinary surgeons in general practice, according to some canine epilepsy experts.
Libromide tablets are intended for use in epileptic dogs which have already commenced therapy with Phenobarbital. Phenobarbital acts to increase the effects of the GABA inhibitory neurotransmitter in the central nervous system. Potassium bromide is synergistic with Phenobarbital and raises the seizure threshold level in epileptic dogs.
Libromide is classified as POM-V and will be available in 325 mg tablets in packs of 100 and 500 tablets.
Rodolfo Cappello DVM PhD DipECVN MRCVS, RCVS and European Specialist in Neurology and Neurosurgery, Head of Neurology Services at North Downs Specialist Referrals, Surrey, said: "I've been successfully using potassium bromide for the treatment of epilepsy in dogs for over 15 years. The main problem has been that it's not been licensed as a medicine. With the launch of Libromide, potassium bromide finally achieves the status of an approved pharmaceutical. We will now be able to monitor quality, efficacy and side effects which will enable us to offer a more professional approach to the treatment of seizures."
Howard Wilder, founder and managing director of Genitrix, added: "Canine epilepsy is an all too common disease with estimates suggesting it affects four in every hundred dogs in the UK. It's also an illness which is not well enough understood with the lack of up to date information available to veterinary surgeons being a contributing factor.
We felt there was an opportunity to bring a licensed product to market and have invested hundreds of thousands of pounds in the process of development and trialling Libromide. We're delighted to make it available to veterinary professionals and hope its launch will be the first step in improving treatment approaches for this distressing disease."
The app, which was designed to provide veterinary surgeons, nurses and receptionists with quick access to up-to-date biological data on a wide range of exotic pets, now contains information about 40 different exotic pet species, from Grey Parrots to Sugar Gliders.
Each species entry offers an overview of the pet, details of common conditions, therapeutics and treatment videos.
Mark, pictured right with a Sulcata tortoise said: "There are a wide range of exotic pets that are becoming increasingly popular with pet owners, yet very few vets understandably have advanced knowledge in this niche area. The "Veterinary Care for Exotics" app for vets means vets, vet nurses and receptionists can now have this knowledge at their fingertips, giving them the reassuring back-up they need when presented with more unusual pets."
The app can be downloaded from Google Play and from Apple's app store, priced at £11.99.
For more information contact Mark Rowland: trinitycpd@gmail.com.
The practice, which is owned by the Linnaeus Group, says it will be refurbishing its existing facilities, extending its premises, hiring more specialist veterinary surgeons, veterinary nurses and support staff and installing state-of-the-art new equipment.
In addition, it plans to refresh its intern programme and launch a nurse training programme.
A six-month programme of building works will include a new reception area, consultation room and medicine and surgery wards.
New services and facilities will include a cat ward, X-ray department and endoscopy and chemotherapy facilities.
Operations manager Daniel Hogan (pictured right), said: "This is a very exciting period as we grow in every possible area and work more closely with referring practices to continue to develop our bespoke and exceptional service for patients and clients.
"Our aim is aspiring and simple: to create the very best referral centre possible by bringing together the expertise of the very best of veterinary professionals supported by the very latest in technological innovation."
For more information about Southfields Veterinary Specialists, visit: www.southfields.co.uk.
Ms Gatehouse faced two charges, the first being that she inaccurately assured another veterinary surgeon that she had vaccinated a horse against influenza and tetanus when she had not, and she subsequently failed to undertake adequate checks to confirm whether she had done so.
The second charge was that she later made a false entry in the same horse’s clinical records to cover up her previous inaccurate statement.
Ms Gatehouse admitted the facts alleged in relation to both charges and also admitted that in relation to the second charge she was guilty of disgraceful conduct in a professional respect.
The Committee, having heard submissions from Counsel for the RCVS and Ms Gatehouse found her guilty of disgraceful conduct in relation to the first charge.
Under the first charge the Committee found that she had breached the RCVS Code of Professional Conduct for Veterinary Surgeons by not keeping clear, accurate and detailed clinical and client records, and by acting in a manner that was likely to undermine public trust in the profession.
They also considered that her falsehood was unpremeditated, and that the decision was made in a moment of panic. Ultimately, however, by claiming the horse was vaccinated to another veterinary surgeon and not taking the necessary steps to confirm this, she failed to put the welfare of the animal first, potentially endangering it and any other horses it came into contact with, as well as potentially jeopardising the position of the veterinary surgeon she confirmed it to.
Having found Ms Gatehouse guilty of serious professional misconduct in relation to both parts of the charge the Committee then considered its sanction against her. In mitigation the Committee considered the fact that she had been in practice for 22 years without any untoward conduct, the testimony of three witnesses who attested to her being an honest and trustworthy practitioner, and the fact that Ms Gatehouse was in a troublesome relationship with the complainant until June 2014 which led her to be reluctant to contact him to correct her initial confirmation.
In summing up Stuart Drummond, Chair of the Committee, said: "The Committee has considers that it is material to have regard to the general emotional state to which the Respondent was reduced by the controlling and debilitating conduct of her then partner when they were living together and the consequential loss of self-esteem and ability to stand up to him and his demands. The deleterious effect of an abusive relationship lingers after such a relationship ends.
"Taking into account this knowledge, the Committee considers that the period of suspension that would, in other circumstances, be entirely merited, can properly be reduced in this instance to reflect the fact that this veterinary surgeon would not have acted as she did during this period but for the fact that her judgement was adversely affected by her experience at the hands of her then former partner.
"The decision is that, whilst it is necessary, in order sufficiently to protect animals and the wider public interest, to impose a period of suspension from practice, that period can be reduced to one of two months. In so concluding the Committee wishes to make it clear that this decision reflects the special features of this case."
Ms Gatehouse can choose to appeal the decision after a period of 28 days.
The Australian company, which launched in the UK offering equine specials in March 2017, says that while some human healthcare companies are authorised to supply veterinary specials under licence in the UK, it is currently the only company in the UK to have specific veterinary authorisation to manufacture sterile specials.
There are six formulations in Bova’s new small animal range with a further 23 formulations scheduled to be introduced in the first half of 2018. However, Bova says that due to advertising restrictions, only verified veterinary surgeons will be able to see its formulation list.
For more information, contact Bova Sales Manager Emma Jones on tel: 07780443731 or Victoria Dawson on 07780443738 or visit www.bova.co.uk.
The company will also be at BSAVA Congress this week on stand 817, where they will be offering the chance to win an afternoon champagne tea at the Ritz.
Zoetis says that Cytopoint works by mimicking the activity of natural antibodies which selectively bind and neutralise canine interleukin-31 (cIL-31), a key cytokine involved in triggering itch in dogs.
The company says that because of the precision and specificity with which Cytopoint acts to target and neutralise cIL-31, it has been shown not to interfere with the immune response, meaning that it does not induce unintended immunosuppression or enhancement.
Dr. Emmanuel Bensignor, a specialist in veterinary dermatology in Paris, France, who participated in field studies conducted in Europe, said: "My personal experience with Cytopoint showed impressive speed of efficacy, significantly reducing itch in dogs from 24 hours onwards.
"Atopic dermatitis is a very common disease in dogs, and the owners I meet are desperate to find a rapid, reliable and safe solution for their suffering dogs. With its once monthly injection, I believe that Cytopoint has the potential to meet pet owners' needs for its convenience.
"European veterinary dermatologists and veterinarians will now have access to a new therapeutic class via this first monoclonal antibody treatment for veterinary use. It is a very exciting innovation which brings a notable improvement to the health and quality of life of the dogs and happiness to their families."
The recommended minimum efficacious dose for the treatment of clinical manifestations of atopic dermatitis in dogs is 1 mg/kg, which can be repeated monthly. Cytopoint will be available in single dose vials containing 10, 20, 30 or 40 mg/kg of lokivetmab.
For more information, visit the European Medicines Agency.
Zoetis has announced the launch of Ketavet.
The intravenous anaesthetic solution containing ketamine is available in 10ml and 50ml presentations. The new product coincides with the re-classification of ketamine as a schedule 2 drug.
Ketavet is a clear, colourless solution for injection containing ketamine 100 mg/ml (equivalent to 115.36 mg/ml ketamine hydrochloride) with benzethonium chloride 0.1 mg/ml as a preservative. It can be used to induce anaesthesia in horses in conjunction with xylazine, detomidine or romifidine.
Ketavet, along with other ketamine containing products, has been moved to Schedule 2 of the Misuse of Drugs Regulations, which took effect from 30 November 2015. This enables tighter controls on the record keeping, prescribing and safe custody of products containing this active. More information on the specific requirements which will need to be met following the schedule change can be found on the VMD website https://www.gov.uk/government/news/amendments-to-the-misuse-of-drugs-regulations-2001
Penny McCann, Equine Product Manager at Zoetis said: "Ketavet is an important product in our anaesthesia portfolio. We are keen to help veterinary surgeons keep up-to-date with the reclassification of ketamine and with this in mind our new product packaging clearly reflects ketamine’s revised status as a schedule 2 drug."
For more information, contact your Zoetis Account Manager.
Cytopoint is an injectable monoclonal antibody therapy for dogs that targets and neutralises the cytokine IL-31, a mediator of allergic itch1.
Zoetis says the new claim was granted following a randomised, double-masked, multi-centred, placebo-controlled study which looked at Cytopoint’s efficacy and safety for the treatment of pruritus associated with allergic dermatitis in client-owned dogs. The study showed that Cytopoint significantly decreased pruritus, and improved skin lesions.2
Allison Henry, Product Manager Companion Animal Dermatology at Zoetis UK, says: "Allergic dermatitis is one of the most common skin conditions in dogs.3 The associated clinical signs – including scratching, hair loss and skin lesions – are disruptive for the dog, impacting their quality of life and that of its owner. Allergic skin disease is one of the most frequent reasons owners present their dog to a veterinarian.
"The licence extension demonstrates further innovation from Zoetis in the field of veterinary dermatology, and across the continuum of care, increasing the treatment options available to manage pruritus. Apoquel remains an ideal choice for short-term control due to its ability to provide rapid itch relief within four hours4 for as little as one day.5 This enables pruritus to be tightly controlled during the diagnostic work up,7 as well as being used for longer term control where tablets are the preferred method of administration.
"The sustained duration of action of Cytopoint makes it better suited to long-term management of pruritus, particularly when administering tablets is a challenge. Other benefits, such as no restrictions on age or with comorbidities, coupled with the flexibility of the new claim, make it a useful treatment at an earlier stage for more unique cases, e.g. young dogs or those with comorbidities."
For further information, contact your Zoetis Account Manager.
watch?v=A8EJ8LpLVzw&feature=youtu.be